SEILA LORENZO HERRERO-rekin lankidetzan egindako argitalpenak (24)

2023

  1. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539

  2. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

    Molecular Cancer, Vol. 22, Núm. 1

  3. Chemo-Immunotherapy: A New Trend in Cancer Treatment

    Cancers, Vol. 15, Núm. 11

  4. Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma

    Cancer Science, Vol. 114, Núm. 1, pp. 48-62

2021

  1. Btla/hvem axis induces nk cell immunosuppression and poor outcome in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 8

  2. Checkpoint inhibition in the fight against cancer: NK cells have some to say in it

    Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance (Elsevier), pp. 267-304

  3. Lag‐3 blockade with relatlimab (Bms‐986016) restores anti‐leukemic responses in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 9

2020

  1. A cytofluorimetric assay to evaluate intracellular cytokine production by NK cells

    Methods in Enzymology (Academic Press Inc.), pp. 343-355

  2. Driver mutations and single copy number abnormalities identify binet stage a patients with chronic lymphocytic leukemia with aggressive progression

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-8

  3. Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay

    Methods in Enzymology (Academic Press Inc.), pp. 483-495

  4. Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 10

  5. Mechanisms of resistance to NK cell immunotherapy

    Cancers, Vol. 12, Núm. 4

  6. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

    Molecular cancer therapeutics, Vol. 19, Núm. 4, pp. 1018-1030

2019

  1. A flow cytometric NK cell-mediated cytotoxicity assay to evaluate anticancer immune responses In vitro

    Methods in Molecular Biology (Humana Press Inc.), pp. 131-139

  2. CD107a degranulation assay to evaluate immune cell antitumor activity

    Methods in Molecular Biology (Humana Press Inc.), pp. 119-130

  3. Immunosurveillance of cancer cell stress

    Cell Stress, Vol. 3, Núm. 9, pp. 295-309

  4. Lectin-like transcript 1 (LLT1) expression is associated with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma

    Archives of Dermatological Research, Vol. 311, Núm. 5, pp. 369-376

  5. NK cell-based immunotherapy in cancer metastasis

    Cancers, Vol. 11, Núm. 1

  6. NK cells in the treatment of hematological malignancies

    Journal of Clinical Medicine, Vol. 8, Núm. 10

  7. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling

    Frontiers in Immunology, Vol. 10